title: Alleviation of bone markers in rats induced nano-zinc oxide by qurecetin and α-lipolic acid.
abstract: The purpose of this study was to evaluate the potential protective effect of qurecetin (Qur) and α-lipolic acid (ALA) to modulate the perturbation of bone turnover which is induced by nano-zinc oxide (n-ZnO). Rats were fasted overnight and randomly divided into two groups: G1, normal healthy animals and the other rats were administered zinc oxide nanoparticles orally by guava in a dose of 600 mg/kg body weight/d for 5 sequential days in Wistar albino male rats. N-ZnO-exposed animals were randomly sub-divided into three groups: G2, n-ZnO-exposed animals; G3, n-ZnO-exposed animals co-treated with Qur (200 mg/kg daily); and G4, n-ZnO-exposed animals co-treated with ALA (200 mg/kg). Qur and ALA were administered orally by guava daily for three sequential weeks from the beginning of the experiment. The results revealed a significant reduction of nitiric oxide (NO) and serum level and comet assay in n-ZnO exposure rats after treatment of Qur and ALA. It was found the alteration of pro-inflammatory markers (tumor necrosis factor alpha; TNF-α, interleukin-6; IL-6 and C-reactive protein; CRP), bone alkaline phosphatase (B-ALP, bone formation marker), and C-terminal peptide type I collagen (CTx, bone resorption marker) levels compared with the normal group. Co-administration of Qur and ALA in n-ZnO-exposed rats significantly alleviated the mentioned alterations of biochemical parameters. These results suggest that Qur and ALA as antioxidant agents may be a candidate for preventive and treatment applications of impaired bone markers induced bone loss caused by nano-particles of metal oxide.
authors: a Nutrition Department , National Research Center , Dokki , Cairo , Egypt.
authors: Hala M
authors: HM
authors: Abdelkarem
authors: b Pharmaceutical Department, Faculty of Pharmacy , King Saud University , Riyadh , Saudi Arabia.
authors: Laila M
authors: LM
authors: Fadda
authors: c Biochemistry Department , National Organization for Drug Control and Research (NODCAR) , Giza , Egypt.
authors: Omyma R
authors: OR
authors: Kaml
mesh_terms: D000818:Animals; D000975:Antioxidants / Q000008:administration & dosage / Q000494:pharmacology*; D015415:Biomarkers / Q000032:analysis / Q000097:blood; D016723:Bone Remodeling / Q000187:drug effects*; D001842:Bone and Bones / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D016207:Cytokines / Q000097:blood; D004249:DNA Damage; D007074:Immunoglobulin G / Q000097:blood; D008297:Male; D053758:Nanoparticles / Q000737:chemistry / Q000633:toxicity*; D009569:Nitric Oxide / Q000097:blood; D011794:Quercetin / Q000008:administration & dosage / Q000494:pharmacology*; D017208:Rats, Wistar; D008063:Thioctic Acid / Q000008:administration & dosage / Q000494:pharmacology*; D015034:Zinc Oxide / Q000737:chemistry / Q000633:toxicity*
chemical_list: D000975:Antioxidants; D015415:Biomarkers; D016207:Cytokines; D007074:Immunoglobulin G; D009569:Nitric Oxide; D008063:Thioctic Acid; D011794:Quercetin; D015034:Zinc Oxide
keywords: bone turnover; n-ZnO; qurecetin and α-lipolic acid and pro-inflammatory